ClinicalTrials.gg
RecruitingNCT07348341CLARITUpdated Jul 23, 2026

Coronary Laser Atherectomy Registry From an International Taskforce

An observational study in Stable Coronary Artery Disease and Acute Coronary Syndromes, sponsored by Ceric Sàrl. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Ceric Sàrl · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Acute Coronary Syndrome with a site in Spain — 13 open to participants now, 16 under way, 1 of them phase 3. Acute Coronary Syndrome · Spain.

Planned enrollment
16th of 25
500 · median 900
Started
2026
with 3 others
Observational
25 of 85
3 open now
Primary completion
2028-07
later than 12 of 15 live
Registered
80th of 85
by date
Lead sponsor
2 of 85
Ceric Sàrl

Among the 85 studies in Acute Coronary Syndrome with a site in Spain, this one is the 16th largest by planned enrollment of the 25 observational ones that give a count, is one of 4 that started in 2026, is one of 25 observational ones, reaches primary completion later than 12 of the 15 other live ones, and was the 80th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

13 of the 85 studies in Acute Coronary Syndrome with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Acute Coronary Syndrome with a site in Spain, or all of them as a file.
02

Study summary

This study is a prospective, investigator-initiated, multi-center, single arm, observational registry of performance of Excimer Laser Coronary Atherectomy (ELCA) in standard use cases of percutaneous coronary intervention (PCI).

Read the detailed description

The primary objective of the CLARIT study is to assess the Safety and Efficacy of ELCA in recognized indications for the device at Index PCI and during the in-hospital stay. The secondary objectives includes the safety and efficacy of ELCA at 30 days and 1 year, as well as the procedural characteristics for the assessment of the learning curve and impact on the catheter lab workflow.

500 patients will be included in 20 sites accorss 8 countries in Europe, United Kingdom and India. The patients included in the study according to eligibility criteria will be followed up one year. The total study duration is 3 years, including 2 years of recruitment.

The follow-up/visit windows include the screening/baseline period, on the day of procedure, discharge; 1 month and 1 year follow-up. The ELCA is to be used following Instruction for uses and follow-up as per hospital standard of care.

03

Conditions studied

  • Stable Coronary Artery Disease
  • Acute Coronary Syndromes

Keywords

  • excimer laser coronary atherectomy
  • ELCA
  • CLARIT
  • coronary artery disease
  • acute coronary syndromes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with stable coronary artery disease or acute coronary syndromes who will be treated with excimer laser coronary atherectomy (ELCA)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects will be included if all the following criteria are met:

  1. Age 18 years or over
  2. Patient willing to be included in the registry
  3. Patients with stable coronary artery disease or acute coronary syndromes with de-novo or intra-stent restenosis (ISR) coronary lesions suitable to be treated with ELCA

    • Non-Crossable with ICI catheter or:
    • Crossable with ICI catheter with significant calcium score suggesting need for calcium modification based on IVUS or OCT criteria and/or
    • Non-Dilatable with 1:1 NC balloon
  4. Mandated use of ICI:

    • Attempted before use of ELCA or
    • Following ELCA and any other calcium modification strategy utilized (to evaluate whether the additional modification demonstrates significant additional modification of the calcium on ICI)
    • Final after DES implantation or prior to use of DCB
  5. Declared PCI strategy (planned use of ELCA, need for IVL/specialty balloons/alternative atherectomy and stent strategy) prior to PCI procedure

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breast feeding
  2. Unable to give
  3. PCI performed without IVCI attempt
  4. No ELCA use
  5. Allergy to clopidogrel, prasugrel or ticagrelor or non-compliance
  6. Post- cardiac arrest or haemodynamic instability
  7. Participation in another trial.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Interventions

  • DeviceExcimer Laser Coronary Atherectomy (ELCA)

    ELCA treat a significant coronary stenosis or recanalize occluded coronary arteries using UV during percutaneous coronary intervention.

06

What researchers measure

Primary outcomes

  1. Procedural success during index PCI

    The primary endpoint of efficacy is procedural Success during index PCI:, which is a combined endpoint of these following events: * Angiographic success defined as residual stenosis \<30% in two orthogonal projections after lesion treatment with ELCA destination therapy with DES or DCB * TIMI 3 flow and absence of ELCA related complications during the procedure * Intra-Coronary Imaging success defined as final MSA \> 5.5mm2 IVUS or 4.5mm2 OCT with \> 80% stent expansion - site reported

    Time frame: During Procedure

  2. Freedom from in hospital Major Adverse Cardiovascular Events

    The primary endpoint of safety is freedom from in-hospital Major Adverse Cardiovascular Events (MACE), including : cardiac death, target vessel myocardial infarction (TVMI), urgent repeat target vessel revascularization (TVR) with either PCI or CABG, and Stroke.

    Time frame: Periprocedural

Secondary outcomes

  1. Composite endpoint of one of events reported

    The secondary endpoint is a composite endpoint of one of these event : Major Adverse Cardiovascular Events (MACE) (including cardiac death, target vessel revascularization, myocardial infarction, target vessel myocardial infarction (TVMI), unplanned hospitalization of unstable angina).

    Time frame: 30 days and 1 year

  2. Success of revascularization: Freedom from Target lesion failure (TLF) events and ICI assessed stent optimization

    This is defined by MSA stent expansion,stent apposition, full lesion coverage with \< 50% plaque burden at proximal and distal references with TIMI 3 flow, no significant edge dissection

    Time frame: 30 days and 1 year

  3. Procedural Characteristic- Cost

    Procedural costs (devices used)

    Time frame: During procedure

  4. Procedural Characteristic- Device success based on maximum fluence

    Device Success based on maximum fluence

    Time frame: During procedure

  5. Procedural Characteristic- Fluoroscopy Time

    Fluoroscopy time

    Time frame: During procedure

  6. Procedural Characteristic- Contrast Volume

    Contrast Volume

    Time frame: During procedure

  7. Procedural characteristic- Device success based on repetition rate

    Device Success based on repetition rate

    Time frame: During procedure

  8. Procedural characteristic- Device success based on pulses number

    Device Success based on number of pulses

    Time frame: During procedure

  9. Procedural characteristic- Device success based on lasing duration

    Device Success in relation to the duration of lasing

    Time frame: During Procedure

  10. Procedural characteristic- Device success based on laser trains number

    Device Success in relation to the number of laser trains

    Time frame: During procedure

  11. Procedural characteristic- Catheter access

    Catheter access : radial or femoral

    Time frame: During Procedure

  12. Requirement of hemodynamic support

    composite of need for pharmacological or mechanical hemodynamic support

    Time frame: During procedure

  13. Marker of the learning curve associated with ELCA- Total procedure time

    The total time of the procedure

    Time frame: During procedure

  14. Marker of the learning curve associated with ELCA- Intra-procedural interval from ELCA decision to post-ELCA intracoronary imaging

    The time between the decision for ELCA to the uses of Intracoronary imaging after ELCA.

    Time frame: During procedure

  15. Marker of the learning curve associated with ELCA- Number of ECLA trains

    The number of ELCA trains, including the number of pulses, settings performed by the clinician.

    Time frame: During procedure

  16. Marker of the learning curve associated with ELCA- Milieu type used during lasing

    The type of milieu used during lasing (blood, saline or contrast)

    Time frame: During procedure

  17. Impact on catheter lab workflow- Lesion preparation strategy

    The change in lesion preparation strategy compared to the operator's initial upfront declared strategy (uses of IVL, specialty balloons or other atherectomy device alongside ELCA).

    Time frame: During procedure

  18. Impact on catheter lab workflow- Stent Strategy

    The change of stent strategy (after ELCA and subsequent ICI) compared to the operator's initial upfront declared strategy.

    Time frame: During procedure

  19. Impact on catheter lab workflow- Procedural duration

    Procedural duration for decision of ELCA to passage of Intracoronary imaging or ballon

    Time frame: During procedure

  20. Intracoronary imaging analysis by the site- Calcium morphology

    Calcium morphology (concentric, eccentric or nodular) reported by the site.

    Time frame: During procedure

  21. Intracoronary imaging analysis by the site- Depth of lesion calcification

    Depth of lesion calcification reported by the site.

    Time frame: During procedure

  22. Intracoronary imaging analysis by the site- Lesion calcification length

    Length of lesion calcification reported by the site

    Time frame: During procedure

  23. Intracoronary imaging analysis by the CoreLab

    calcium burden (%)

    Time frame: During procedure

  24. Intracoronary imaging analysis by the CoreLab

    calcium depth (mm)

    Time frame: During Procedure

  25. Intracoronary imaging analysis by the CoreLab

    impact of OAS and other devices on calcium

    Time frame: During procedure

  26. Intracoronary imaging analysis by the CoreLab

    minimal stent area (mm²)

    Time frame: during procedure

  27. Intracoronary imaging analysis by the CoreLab

    stent expansion (%)

    Time frame: During Procedure

  28. Intracoronary imaging analysis by the CoreLab

    presence of edge dissection

    Time frame: During Procedure

  29. Intracoronary imaging analysis by the CoreLab

    presence of stent malposition

    Time frame: During procedure

  30. Intracoronary imaging analysis by the CoreLab

    maximal eccentricity index

    Time frame: During procedure

07

Study locations

1 of 1 sites recruiting
  • La Paz Universtity Hospital
    Madrid, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.

Of 34 industry-sponsored observational studies under Acute Coronary Syndrome, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's planned 24 months is below that.

Counting every sponsor, half of 277 studies reached it within 35 months; a quarter within 18 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Jan 16, 2026
StartActual
Jul 20, 2026
Primary completionEst.
Jul 30, 2028
CompletionEst.
Jul 30, 2029
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07348341
Lead sponsor
Ceric Sàrl
Collaborators
Philips Medical Systems, European Cardiovascular Research Center
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Jul 20, 2026
Primary completion
Jul 30, 2028 (estimated)
Completion
Jul 30, 2029 (estimated)
Last update
Jul 23, 2026

Study contacts

Julie FAURE
Contact
jfaure@cerc-europe.org
+33 (0)675574485
Phani Kondamudi
Contact
pkondamudi@cerc-europe.org
+33 (0)6 60 05 55 12
Peter O'kane, Professor
study chair · Dorset Heart Centre, The Royal Bournemouth Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion